However, the gastric emptying effect of GLP-1 medications can affect levothyroxine absorption timing
In a study of transgenic mice with a Kras G12D mutation which induces PanINs and eventually pancreatic cancer, treatment with exendin-4 increased higher grade PanIN lesions (35, 38)
Real-World Clinical Practice Branded GLP-1 medications (semaglutide, tirzepatide) have defined BMI thresholds in their FDA labeling: BMI of 30 kg/m or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or cardiovascular disease
As of mid-2025, retatrutide is not approved by the MHRA or any other regulatory authority, and all dosing information derives exclusively from clinical trial protocols
Greenselect Phytosome for Borderline Metabolic Syndrome